Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means the agency’s own highest classification or reported deaths or serious injuries, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
Akorn Inc. is recalling 29,972 bottles of 5% Sodium Chloride Ophthalmic Solution because the product concentration is less than the labeled amount.
Par Pharmaceutical is recalling Gildess 1.5/30 tablets because they contain subpotent levels of ethinyl estradiol. The recall covers specific lots distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess 1/20 tablets because they contain subpotent levels of ethinyl estradiol. The recall covers 393,981 tablets distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess 24 FE 1.5/30 oral contraceptives because the ethinyl estradiol component is subpotent. The recall covers 44,127 tablets distributed nationwide and in Puerto Rico.
Taro Pharmaceuticals is recalling specific lots of Desoximetasone Cream 0.05% because they failed stability specifications for homogeneity.
Taro Pharmaceuticals is recalling specific lots of Desoximetasone Cream 0.25% because they failed stability tests for moderate separation.
Par Pharmaceutical is recalling Gildess FE 1/20 tablets because the ethinyl estradiol component is subpotent. The recall covers 822,009 tablets distributed nationwide and in Puerto Rico.
Actavis is recalling 15,984 bottles of Ramipril Capsules because they were labeled with an incorrect expiration date of 03/18 instead of 09/17.
Par Pharmaceutical is recalling Gildess FE 1.5/30 tablets because they may contain subpotent levels of ethinyl estradiol.
Boehringer Ingelheim is recalling 2,562 bottles of 75 mg Persantine tablets because 50 mg tablets were found inside the bottles.
Boehringer Ingelheim is recalling 6,400 bottles of 75 mg Dipyridamole tablets because 50 mg Persantine tablets were found inside the bottles.
Pharmatech LLC is recalling Poly-Vita Drops with Iron as a precaution due to potential contamination with Burkholderia cepacia.
Pharmatech LLC is recalling Pedia D-Vite Drops as a precaution due to potential contamination with Burkholderia cepacia.
Pharmatech LLC is recalling 8,712 bottles of Pedia Tri-Vite Drops due to a potential risk of contamination with Burkholderia cepacia.
Janssen Ortho L.L.C. is recalling Invokamet tablets because Xarelto prescribing information outserts may be affixed to the bottles instead of the correct Invokamet inserts.
SOS Telecom Inc. is recalling Super Samurai-X dietary supplements because FDA testing found undeclared sildenafil and/or its analogs.
SOS Telecom Inc. is recalling Ninja-X dietary supplements because FDA analysis found undeclared sildenafil or its analogs. The product was marketed without an approved NDA or ANDA.
SOS Telecom Inc. is recalling Tiger-X dietary supplements because FDA testing found undeclared sildenafil or analogs. The product was marketed without an approved NDA or ANDA.
SOS Telecom Inc. is recalling Ginseng Power-X capsules because FDA testing found undeclared sildenafil or analogs.
Dream Body Weight Loss is recalling Dream Body Extreme Gold capsules because they contain undeclared sibutramine and were marketed without FDA approval.
Dream Body Weight Loss is recalling Dream Body 450 mg capsules because they contain undeclared sibutramine and were marketed without FDA approval.
Dream Body Advanced 400 mg capsules are being recalled because they contain undeclared sibutramine and were marketed without an approved NDA/ANDA.
Supernus Pharmaceuticals is recalling Trokendi XR (topiramate) capsules because they failed to meet assay specifications.
Arbor Pharmaceuticals is recalling Cetylev (acetylcysteine) effervescent tablets because incomplete seals on the blister packaging allow moisture to enter, causing the tablets to swell.
DNE Nutraceuticals Inc. is recalling Adwe Prenatal tablets due to a concern regarding the potency of folic acid. The recall affects 1,200 bottles distributed in New York.